Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of innovative cancer therapeutics. It aims to improve treatment outcomes for patients through its scientific advancements. Sunesis Pharmaceuticals, Inc.

specializes in developing targeted therapies for cancer treatment. Founded in 1987, the company is headquartered in South San Francisco, US. Sunesis has undergone shifts in focus over the years, including its transition to a publicly traded company in September 2005, raising USD 42 million in an IPO by selling 6 million shares at USD 7 per share. The company has secured funding through multiple rounds, with a total amount raised of USD 43.

50 mn, including its most recent round of Venture Debt where it raised USD 15. 00 mn from Bridge Bank in 2005. The founder's specific history is not detailed in the available data. Sunesis Pharmaceuticals, Inc.

is dedicated to developing innovative treatments specifically targeting cancer. It engages in research to create novel therapies that aim to enhance patient care and treatment efficacy. The company's product pipeline includes various drug candidates designed to address different cancer types, with a focus on establishing a strong presence in oncology. In the most recent fiscal year, Sunesis Pharmaceuticals, Inc.

reported revenue of USD 120,000 with an EBITDA of USD -22,268,000, indicating ongoing investments in research and development for their therapeutic offerings. Sunesis Pharmaceuticals is focused on advancing its product pipeline with plans to launch new cancer therapeutics, although specific upcoming products and their release dates have not been disclosed. The company is exploring expansion opportunities in new geographic markets to reach a broader patient population. The recent funding round will support these initiatives, allowing for continued innovation and development in their oncology-focused projects.